Three decades operating in FDA-regulated healthcare and biotech. Current focus spans frontier exosome biologics, investigational oncology, interventional procedures, and medical-legal services. This page is the living resume, kept current and verifiable.
Wharton’s jelly mesenchymal stem cell–derived exosome biologics on the FDA 351(a) BLA regulatory pathway. IND-enabling work under 21 CFR 1271 and 21 CFR 312, with CMC, preclinical, and clinical components organized for CBER review.
Targeted Osmotic Lysis cancer therapy program. Investigational use under FDA oncology pathway, evidence-based protocol design.
Interventional procedure operations supporting the Discseel Procedure for chronic low-back pain (annular tear sealing with fibrin), and adjunctive regenerative protocols.
Personal-injury case-management support: provider scheduling, letter-of-protection administration, and case-to-settlement coordination for plaintiff counsel.
Substack publication on second chances, frontier biotech operating, and the realities of building post-disclosure. thehillmanletter.substack.com
AI-assisted protocol research for regenerative medicine in professional sports. Evidence-based protocol design from peer-reviewed data, compiled for IND and IRB submission. aiapro.org
Frontier biologics, investigational oncology, interventional procedures, and medical-legal services. Operating focus on FDA-regulated and IND/IRB-pathway programs.
Pleaded guilty October 2018 to two federal conspiracy charges. Sentenced December 2019 to 66 months. Cooperated with the government. Federal sentence fully discharged. Disposition disclosed openly below and on the public record site.
Multiple operating roles across pharmacy, laboratory, and healthcare-services entities in Texas, building the operating foundation that underwrites the current frontier-biotech work.
A consistent record of using the federal courts on the consumer side against large institutional counterparties where covert tracking or privacy violations harm ordinary people.
No. 1:10-cv-08315 (S.D.N.Y., Hon. Denise L. Cote). Federal class action over HTML5 device-identifier respawning. Court-approved class-wide settlement. Case is cited in CLE curricula for federal judges and trial lawyers (American Inns of Court) and discussed in academic privacy literature (Stanford Center for Internet and Society; Schneier on Security).
No. 4:11-cv-02157 (N.D. Cal.). Federal privacy class action filed on behalf of named family-member plaintiffs over Android operating-system location-data collection. Class counsel included Joseph H. Malley (Dallas), Fears Nachawati (Dallas), Audet & Partners (San Francisco), Lockridge Grindal Nauen (Minneapolis, liaison), Wood Law Firm (Birmingham), Terrell Law Group (Oakland), Mayer Law Group (Charleston).
N.D. Cal., Hon. Virginia DeMarchi. $135 million class settlement preliminarily approved March 2026. Final-approval hearing June 23, 2026. Class period November 12, 2017 through date of final order.
Claim administration at googleassistantprivacylitigation.com. Class allegations over Google Assistant recording without trigger-word activation.
Ongoing support.
Ongoing support. Aleph’s mission is direct service to families of incarcerated individuals and to people reentering society.
Ongoing support.
Founded scholarship and biotech grant programs. See andrewhillman.org for details.
Supporter of KidSwing for Scottish Rite for Children.
Member.
Available for expert-witness retention and advisory engagements in healthcare regulatory, FDA biologics pathway strategy, pharmacy and laboratory operations, and healthcare-fraud compliance design. Texas Notary Public. Engagements through andrewhillmanadvisor.com.